v3.23.1

Unaudited Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 1,105	$ 3,919
Operating expenses:
Research and development	36,417	27,930
General and administrative	13,392	8,085
Total operating expense	49,809	36,015
Loss from operations	(48,704)	(32,096)
Other income:
Interest income	7,828	30
Total other income	7,828	30
Net loss	(40,876)	(32,066)
Other comprehensive gain:
Unrealized gain on marketable securities, net	197
Comprehensive loss	$ (40,679)	$ (32,066)
Net loss per share, basic	$ (0.86)	$ (0.82)
Net loss per share, diluted	$ (0.86)	$ (0.82)
Weighted average shares outstanding, basic	47,461,230	39,006,794
Weighted average shares outstanding, diluted	47,461,230	39,006,794

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Prometheus Biosciences, Inc. 10-Q